IP Library Granted Patent US 7,560,559
Granted Patent B2
US 7,560,559 · App. 10/553,069 · Granted Jul 14, 2009

Polymorphic form of montelukast sodium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,560,559
App. No.
10/553,069
Granted
Jul 14, 2009
Kind
B2
Abstract

The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium: acetonitrile solvates, which are intermediates in the formation of crystalline montelukast sodium.

Claims (127)

1. Form B montelukast sodium characterized as having an x-ray powder diffraction pattern peak position substantially as shown:

2 θ

d spacing (A)

Intensity

5.4

16.4

s

5.7

15.6

vs

9.5

9.3

m

10.4

8.5

m

17.1

5.2

s

18.7

4.73

s

21.6

4.11

 s.

2. Montelukast sodium:acetonitrile monosolvate.

3. Montelukast sodium:acetonitrile monosolvate of claim 2 characterized by having 13 C solid-state CPMAS NMR chemical shifts in ppm at 72 (sharp triplet), 74 (sharp triplet), 77 (sharp triplet), 179 (sharp doublet), and 182 (sharp doublet).

4. Montelukast sodium:acetonitrile monosolvate of claim 2 further characterized by having X-ray powder diffraction peaks substantially as shown:

2 θ

d spacing (Å)

Intensity

4.30

20.5

vs

5.9

14.9

s

6.2

14.3

s

6.8

13.0

w

7.3

12.0

w

10.5

8.4

m

11.0

8.0

w

12.7

7.0

m

16.2

5.5

s

18.1

4.90

w

18.7

4.74

w

21.6

4.12

w

23.4

3.80

w

23.9

3.72

 w.

5. Montelukast sodium:acetonitrile hemisolvate.

6. Montelukast sodium:acetonitrile hemisolvate of claim 4 characterized by having 13 C solid-state CPMAS NMR chemical shifts in ppm at 27 (well resolved) and 55 (well resolved), referenced by setting the carbonyl resonance of glycine to 176.08.

7. Montelukast sodium:acetonitrile hemisolvate of claim 4 characterized by having X-ray powder diffraction peaks substantially as shown:

2 θ

d spacing (Å)

Intensity

4.57

19.3

s

5.3

16.7

s

5.6

15.7

vs

6.5

13.6

m

9.4

9.4

m

10.3

8.6

w

11.6

7.6

m

14.1

6.3

w

14.5

6.1

m

15.1

5.8

w

16.2

5.5

m

17.0

5.2

m

18.5

4.79

s

20.8

4.26

m

21.3

4.17

 s.

8. A method for the preparation of montelukast sodium Form A substantially free of amorphous montelukast sodium comprising: 1) collecting montelukast sodium:acetonitrile monosolvate; and 2) removing acetonitrile from the collected monosolvate.

9. A method for the preparation of montelukast sodium Form A substantially free of amorphous montelukast sodium comprising: 1) contacting amorphous montelukast sodium or a mixture of amorphous montelukast sodium and montelukast sodium Form A with acetonitrile to form montelukast sodium:acetonitrile monosolvate; 2) collecting said monosolvate; and 3) removing acetonitrile from the collected monosolvate.

10. The method of claim 8 wherein a mixture of amorphous montelukast sodium and montelukast sodium Form A is used in step 1).

Assignments (3)
CHANGE OF NAME Recorded Jan 29, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023870/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2006
From: BAZIN, CYNTHIA; CLAS, SOPHIE-DORTHEE; DALTON, CHAD
To: MERCK FROSST CANADA & CO.
Reel/Frame 017307/0742 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2006
From: CHOU, JUN-HONG; GENTZLER, MICHAEL B.; MICHAELS, JAMES N.; WU, MICHAEL GUOJIE
To: MERCK & CO., INC.
Reel/Frame 017312/0578 →